(23 days)
IMMUNO-TROL™ Low Cells is an assayed, lysable whole blood quality control product for immunophenotyping analysis using monoclonal antibody reagents and flow cytometry. It provides a positive cell control that is processed in the same manner as a whole blood sample. This allows verification of reagent performance, and the methods used for staining of targeted cells, lysing erythrocytes, and analyzing samples by flow cytometry. The product is intended "For In Vitro Diagnostic Use."
IMMUNO-TROL™ Low Cells is a liquid preparation of stabilized erythrocytes and leukocytes in a stabilizing solution containing BSA.
The provided text is a 510(k) summary for the IMMUNO-TROL™ Low Cells device. It states that the device is "substantially equivalent" to a predicate device and provides performance data primarily related to stability. However, the document does not contain specific acceptance criteria or an explicit study describing how the device quantitatively meets those criteria in terms of accuracy, precision, or other performance metrics for immunophenotyping.
The summary is primarily focused on demonstrating equivalence to an existing device (IMMUNO-TROL™ Cells) with the only noted difference being a "reduced level of CD4". The "Summary of Performance Data" section merely states: "The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to products already in commercial distribution. Stability studies of IMMUNO-TROL™ Low Cells support the Beckman Coulter stability claims of 90 days (open vial) and 9 months (closed vial)."
Therefore, I cannot provide a table of acceptance criteria and reported device performance as this information is not present in the provided document. The other requested information (sample size, experts for ground truth, adjudication, MRMC study, standalone performance, type of ground truth, training set size, and ground truth for training set) is also not detailed in this 510(k) summary document, as such detailed study breakdowns are not typically included in these summaries but would be part of the full 510(k) submission.
{0}------------------------------------------------
Summary of Safety & Effectiveness IMMUNO-TROL™ Low Cells
DEC 1 3 2001
1.0 Submitted By:
Lourdes Coba Senior Regulatory Affairs Specialist Beckman Coulter, Inc. 11800 SW 147 Avenue, M/C: 31-B06 Miami, Florida 33196-2500 Telephone: (305) 380-4079 FAX: (305) 380-3618
2.0 Date Submitted:
November 19, 2001
Device Name(s): 3.0
3.1 Proprietary Names
IMMUNO-TROL™ Low Cells
Classification Name 3.2
Hematology quality control mixture (21 CFR § 864.8625)
4.0 Predicate Device:
| Candidate(s) | Predicate | Manufacturer | Docket Number |
|---|---|---|---|
| IMMUNO-TROL TM LowCells | IMMUNO-TROLTMCells | Beckman Coulter, Inc. | K984216 |
5.0 Description:
IMMUNO-TROL™ Low Cells is a liquid preparation of stabilized erythrocytes and leukocytes in a stabilizing solution containing BSA.
{1}------------------------------------------------
6.0 Intended Use:
IMMUNO-TROL™ Low Cells is an assayed, lysable whole blood quality control nroduct for immunophenotyping analysis using monoclonal antibody reagents prouder lerthmetry. It provides a positive cell control that is processed in the and manner as a whole blood sample. This allows verification of reagent same manno, and the methods used for staining of targeted cells, lysing erythrocytes, and analyzing samples by flow cytometry. The product is intended "For In Vitro Diagnostic Use."
Clinical Significance:
Immunophenotyping analysis by flow cytometry involves the identification and immanophonotyping of targeted cells in whole blood samples. Whole blood samples are stained with monoclonal antibodies and erythrocytes are lysed prior to flow cytometric analysis. A positive control is required to verify reagent performance, sample performance, sample preparation methods, and staining procedures. A positive control should mimic a representative whole blood sample in terms of monoclonal antibody performance, erythrocyte lysing, and flow cytometric analysis.
7.0 Comparison to Predicate(s):
IMMUNO-TROL™ Low Cells is identical to the current IMMUNO-TROL™ Cells. The only difference is the reduced level of CD4.
8.0 Summary of Performance Data:
The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to products already in commercial distribution. Stability studies of IMMUNO-TROL™ Low Cells support the Beckman Coulter stability claims of 90 days (open vial) and 9 months (closed vial).
This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing requlation 21 CFR 807.92.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image is a black and white seal for the Department of Health & Human Services - USA. The seal is circular with text around the perimeter. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA". In the center of the seal is a stylized image of an eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Lourdes Coba Senior Regulatory Affairs Specialist Beckman Coulter, Inc. 11800 SW 147 Avenue, M/C: 31-B06 Miami, Florida 33196-2500
DEC 1 3 2001
K013842 Re:
Trade/Device Name: IMMUNO-TROL™ Low Cells Regulation Number: 21 CFR § 864.8625 Regulation Name: Hematology Quality Control Mixture Regulatory Class: II Product Code: JPK Dated: November 19, 2001 Received: November 20, 2001
Dear Mr. Coba:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
page 1 of 1
510(k) Number (if known):
Device Name: IMMUNO-TROL™ Low Cell
Indications for Use:
IMMUNO-TROL™ Low Cells is an assayed, lysable whole blood quality control product for immunophenotyping analysis using monoclonal antibody reagents and flow cytometry. It in manolitive cell control that is processed in the same manner as a whole blood sample. This allows verification of reagent performance, and the methods used for staining of targeted cells, lysing erythrocytes, and analyzing samples by flow cytometry. The product is intended "For In Vitro Diagnostic Use."
Immunophenotyping analysis by flow cytometry involves the identification and enumeration infinancells in whole blood samples. Whole blood samples are stained with monoclonal antibodies and erythrocytes are lysed prior to flow cytometric analysis. A positive cell control is required to verify reagent performance, sample performance, sample prenaration, methods, and staining procedures. A positive cell control should mimic a representative whole blood sample in terms of monoclonal antibody performance, erythrocyte lysing, and flow cytometric analysis.
864.8625 Hematology quality control mixture
Identification. A hematology quality control mixture is a device used to ascertain the accuracy and precision of manual, semiautomated, and automated determinations of cell parameters such as white cell count (WBC), red cell count (RBC), platelet count (PLT), hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC).
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|---|---|
| [Signature] (Division Sign-Off) | |
| Division of Clinical Laboratory, Devices | |
| 510(k) Number | K013842 |
| Prescription Use(per 21 CFR 801.109) | OR | Over-the-Counter UseOptional Format 1-2-96 |
|---|---|---|
| [X] | [ ] |
§ 864.8625 Hematology quality control mixture.
(a)
Identification. A hematology quality control mixture is a device used to ascertain the accuracy and precision of manual, semiautomated, and automated determinations of cell parameters such as white cell count (WBC), red cell count (RBC), platelet count (PLT), hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC).(b)
Classification. Class II (special controls). Except when intended for use in blood components, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.